Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT
- 23 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (17), 1447-1451
- https://doi.org/10.1182/blood.2019004315
Abstract
Human herpesvirus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT). There are no randomized studies of antiviral treatments to prevent HHV-6B reactivation. Brincidofovir has high in vitro activity against HHV-6B and other DNA viruses, but its in vivo activity for HHV-6B has not been demonstrated. We performed a post hoc analysis of a randomized controlled trial of twice-weekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of brincidofovir on HHV-6B reactivation. We included patients randomized within 2 weeks of HCT and who received at least 6 consecutive doses of study drug after randomization. We tested plasma for HHV-6B through week 6 post-HCT. The cohort consisted of 92 patients receiving brincidofovir and 61 receiving placebo. The cumulative incidence of HHV-6B plasma detection through day 42 post-HCT was significantly lower among patients receiving brincidofovir (14.2%) compared with placebo (32.4%; log-rank, 0.019). In an adjusted Cox model, brincidofovir exposure remained associated with a lower hazard for HHV-6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80). In conclusion, brincidofovir prophylaxis reduced HHV-6B reactivation after allogeneic HCT in a post hoc analysis of a randomized controlled trial. These data support the study of intravenous brincidofovir for HHV-6B prophylaxis.This publication has 24 references indexed in Scilit:
- Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2019
- First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell TransplantationAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal studyBone Marrow Transplantation, 2019
- Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2018
- Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantationBlood Advances, 2018
- Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantationJournal of Allergy and Clinical Immunology, 2017
- Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 2017
- The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortalityBlood, 2017
- HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysisBone Marrow Transplantation, 2012
- Human Herpesvirus-6 Cytopathic InclusionsThe American Journal of Dermatopathology, 2012